CREATE Medicines

Cell therapy is hitting the limits of custom manufacturing. @CREATEMedicines raised a $122M Series B led by Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners as Daniel Getts and team build in vivo immune programming and mRNA-LNP therapies that engineer immune cells directly inside the body. The next cell therapy breakthrough will not just be biological. It will be operational, repeatable, and fast enough to change the economics of medicine.

@CREATEMedicines secures $122M Series B to advance in vivo CAR-T for autoimmune disease and oncology. Could this reshape industry R&D strategy? Learn more: hubs.li/Q04gDcGY0 #InVivoCART #AutoimmuneDisease #Oncology #mRNA #LNP #BiotechFunding #CellTherapy #Immunotherapy

Create Medicines fashions $122M fundraise for in vivo CAR-T dreams fiercebiotech.com/biotech/create…

CREATE Medicines Strengthens Clinical and Scientific Advisory Board with Appointment of Georg Schett, MD, Margrit Wiesendanger, MD, PhD, and Christopher Jewell, PhD dlvr.it/TSXTh4

CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates through human trials. trib.al/O0Wveie

Read the full press release: prnewswire.com/news-releases/…

World class science starts with world class leaders. #CREATEMedicines is expanding our Clinical and Scientific Advisory Board with appointments of Georg Schett, MD, Margrit Wiesendanger, MD, PhD, and Christopher Jewell, PhD. Their expertise will be invaluable as we advance our in vivo #CART pipeline to the next phase of development.

Proceeds will advance repeat dose capable CD19 targeted in vivo CAR-T program for autoimmune disease, expansion of its CD19 x BCMA programs, and continued progress in oncology. Read the full press release: prnewswire.com/news-releases/…

#CREATEMedicines announces close of $122M Series B financing, co-led by Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners.

#CREATEMedicines presenting at Day 3 of #PEGSBoston this Thursday, May 14. CSO Robert Hofmeister, PhD will discuss how CREATE is rethinking cell therapy. CREATE’s iterative platform enables delivery of repeatable and safe in vivo CAR therapies, demonstrated in over 50 patients. #CellTherapy #Immunotherapy

#CREATEMedicines will be at the ARA Annual Scientific Meeting in Gold Coast from May 16–19. Daniel Getts, CEO and Adam Raff, SVP, Autoimmune Clinical Development, will be on the ground connecting with the Australian rheumatology community.

CREATE Medicines CEO Daniel Getts is presenting at ChinaBio in Shanghai at 9:30 am CST, sharing the science and development strategy behind CREATE’s multi-immune in vivo CAR platform.

#CREATEMedicines CEO Daniel Getts, PhD will be presenting at the Cell & Gene Therapy Summit at #ChinaBio in Shanghai on April 29, sharing the science and development strategy behind our in vivo CAR platform, from concept to clinical proof of concept. Reach out at partnering@createmedicines.com.

The first selective multi-immune #InVivoCAR therapy has entered the clinic. #CREATEMedicines has dosed the first patient in our Phase 1/2 trial of MT-304, which programs NK and myeloid cells to coordinate innate immunity against HER2+ tumors. Read more: prnewswire.com/news-releases/… #HER2 #BreastCancer #BCSM

Presenting at AACR today. Poster 0144/18 — In Vivo CAR mRNA Engineering of T Cells and Myeloid Cells Enables Potent Anti-Tumor Control of Solid Cancers. Session PO.IM01.07, 2:00–5:00 PM PT. Come find us! #InVivoCAR #AACR #AACR26 #CREATEMedicines

CREATE Medicines is at AACR in San Diego with two posters — in vivo CAR-T/multi-immune data and our RetroT platform. April 19 & 20. Read more: prnewswire.com/news-releases/… Reach out: partnering@createmedicines.com #InVivoCAR #AACR #AACR26

We're heading to Bernstein's Best of Biotech Symposium on April 16. Interested in connecting with CREATE Medicines CEO Daniel Getts? Reach out at partnering@createmedicines.com. #Biotech #BestOfBiotech

CREATE Medicines announced new data showing complete B cell depletion in NHPs using its proprietary in vivo CAR-T platform. The data will be presented at the Keystone Symposia: Emerging Cell Therapies conference on Monday, February 2, 7:30 p.m. MST in Banff, Alberta. Highlights include: * Complete B cell depletion with a TCR-specific CAR and a conventional 41BBζ CAR * Targeted RNA-LNP immune programming *Flexible receptor architecture across oncology & autoimmunity prnewswire.com/news-releases/… #KSCellTherapy26